Drug intelligence / Profile preview

MAN-19

Development stage: Unknown
Lead developer: Mannin Research
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

**MAN-19 is a recombinant fusion protein** designed to treat patients with Acute Respiratory Distress Syndrome (ARDS), particularly those caused by viral infections such as COVID-19. It does not target the virus directly but strengthens blood vessels and protects against complications like ARDS, breathing problems, sepsis, and other infections that can lead to organ failure. The primary goal is to keep patients out of the ICU and off ventilators[2].

Brand names: MAN-19MAN19MAN 19
Other names: MAN-19MAN19MAN 19

Targets

TEK (Tie2)

Beyond the preview

Go deeper on MAN-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAN-19.

Explore the full profile